Subscribe to RSS

DOI: 10.1055/s-0045-1815706
Impact of FIGO 2023 Staging on MRI Evaluation of Endometrial Cancer: Highlighted Version
Authors
Abstract
The 2023 revision of the International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial carcinoma (EC) has introduced significant updates, including refined anatomic definitions and the incorporation of molecular subtypes such as POLE mutations, mismatch repair deficiency, and p53 abnormalities. Magnetic resonance imaging (MRI) remains the preferred modality for preoperative staging of EC due to its superior soft tissue contrast and functional imaging capabilities. This review discusses the technical considerations for MRI acquisition, with particular emphasis on the impact of the revised staging system on imaging interpretation. It highlights the role of MRI in evaluating eligibility for fertility-sparing treatments and in posttreatment surveillance. Radiologists must be familiar with these changes to ensure accurate staging and optimal patient management. Lastly, it elucidates the utility of imaging biomarkers such as apparent diffusion coefficient values, tumor size, and patterns of spread as potential surrogates for histologic and molecular classification. Integrating molecular profiling with MRI interpretation represents a critical advancement toward risk-adapted therapeutic strategies in endometrial cancer.
Keywords
endometrial carcinoma - FIGO 2023 staging - magnetic resonance imaging (MRI) - molecular classification - radiogenomicsPublication History
Article published online:
16 January 2026
© 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Maheshwari E, Nougaret S, Stein EB. et al. Update on MRI in evaluation and treatment of endometrial cancer. Radiographics 2023; 43 (04) 1103-1126
- 2 Zhang L, Liu L. Evaluation of multi-parameter MRI in preoperative staging of endometrial carcinoma. J Magn Reson Imaging 2022; 56 (02) 487-495
- 3 Cui T, Shi F, Gu B. et al. Peritumoral enhancement for the evaluation of myometrial invasion in low-risk endometrial carcinoma on dynamic contrast-enhanced MRI. Front Oncol 2022; 11: 793709
- 4 Berek JS, Matias-Guiu X, Creutzberg C. et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023; 161 (Suppl. 01) 27-44
- 5 Reinhold C, Ueno Y, Akin EA. et al; Expert Panel on GYN and OB Imaging. ACR Appropriateness Criteria® pretreatment evaluation and follow-up of endometrial cancer. J Am Coll Radiol 2020; 17 (11S): S472-S486
- 6 Nougaret S, Horta M, Sala E. et al. Endometrial cancer MRI staging: updated guidelines of the European Society of Urogenital Radiology. Eur Radiol 2019; 29 (02) 792-805
- 7 Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15 (01) 10-17
- 8 Luna C, Balcacer P, Castillo P, Huang M, Alessandrino F. Endometrial cancer from early to advanced-stage disease: an update for radiologists. Radiographics 2020; 40 (05) 1403-1424
- 9 WHO Classification of Tumours Editorial Board. Female Genital Tumours. WHO Classification of Tumours. 5th ed. Vol. 4.. Lyon: IARC Press; 2020: 559-596
- 10 Deng L, Wang QP, Yan R. et al. The utility of measuring the apparent diffusion coefficient for peritumoral zone in assessing infiltration depth of endometrial cancer. Cancer Imaging 2018; 18 (01) 23
- 11 Akçay A, Gültekin MA, Altıntaş F. et al. Updated endometrial cancer FIGO staging: the role of MRI in determining newly included histopathological criteria. Abdom Radiol (NY) 2024; 49 (10) 3711-3721
- 12 Lavaud P, Fedida B, Canlorbe G, Bendifallah S, Darai E, Thomassin-Naggara I. Preoperative MR imaging for ESMO-ESGO-ESTRO classification of endometrial cancer. Diagn Interv Imaging 2018; 99 (06) 387-396
- 13 Ma X, Shen M, He Y. et al. The role of volumetric ADC histogram analysis in preoperatively evaluating the tumour subtype and grade of endometrial cancer. Eur J Radiol 2021; 140: 109745
- 14 Ozturk M, Kalkan C, Danaci M, Kefeli M. Diffusion-weighted MRI at 3T in endometrial cancer: correlation of apparent diffusion coefficient with histopathological prognostic parameters. J Coll Physicians Surg Pak 2021; 31 (12) 1399-1405
- 15 Jin X, Yan R, Li Z. et al. Evaluation of amide proton transfer-weighted imaging for risk factors in stage I endometrial cancer: a comparison with diffusion-weighted imaging and diffusion kurtosis imaging. Front Oncol 2022; 12: 876120
- 16 Bakir VL, Bakir B, Sanli S. et al. Role of diffusion-weighted MRI in the differential diagnosis of endometrioid and non-endometrioid cancer of the uterus. Acta Radiol 2017; 58 (06) 758-767
- 17 Reyes-Pérez JA, Villaseñor-Navarro Y, Jiménez de Los Santos ME, Pacheco-Bravo I, Calle-Loja M, Sollozo-Dupont I. The apparent diffusion coefficient (ADC) on 3-T MRI differentiates myometrial invasion depth and histological grade in patients with endometrial cancer. Acta Radiol 2020; 61 (09) 1277-1286

